Skip to main content
    R

    Rein Therapeutics Inc (RNTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.36
    -0.04 (-10.90%)

    Market Cap: $34.51M

    Last updated: Nov 17, 2026 at 4:29 PM ET

    Rein Therapeutics Inc (RNTX) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Rein Therapeutics (RNTX) has a market cap of $34.51M and an enterprise value of $33.56M. Its share count is up 235.06% from a year earlier.

    Total Valuation

    Enterprise value is 2.73% below the market cap, as cash exceeds debt.

    Market Cap$34.51M
    Enterprise Value$33.56M
    Latest price (Nov 17, 2026)$0.36

    Key Dates

    The next earnings report is expected on Mar 24, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 24, 2027 (expected)
    Last Earnings DateNov 16, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 31.66% in the quarter ended Sep 30, 2026 and grew 101.92% a year over 2 years.

    Shares Outstanding88.33M
    Shares Change (YoY)+235.06%
    Shares Change (QoQ)+31.66%
    Share Count Growth (2Y CAGR)+101.92%

    Price Statistics

    The stock is down 71.49% over 52 weeks and trades 47.83% below its 50-day average.

    Beta (1Y)2.38
    52-Week Change-71.49%
    1-Month Change-35.43%
    3-Month Change-55.00%
    6-Month Change-64.18%
    5-Year Change-96.15%
    10-Year Change-70.12%
    Total Return (1Y)-71.49%
    Total Return (3Y CAGR)-42.95%
    Total Return (5Y CAGR)-51.89%
    Max Drawdown (1Y)-81.04%
    Max Drawdown (3Y)-94.86%
    Sharpe Ratio (1Y)-1.34
    Correlation with SPY (1Y)0.36
    50-Day Average$0.69
    200-Day Average$0.99
    52-Week Range$0.28 to $2.10
    RSI (14 Days)24.5
    Average Volume (20 Days)857.63K

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 6.57x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio6.57x
    Quick Ratio6.57x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is -640.11% and return on assets is -83.66% over the last 12 months.

    Return on Equity (ROE)-640.11%
    Return on Assets (ROA)-83.66%
    Return on Capital Employed (ROCE)-93.68%
    ROIC (5Y Average)177.56%

    Scores

    RNTX has a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.

    Piotroski F-Score1 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was $0 over the last 12 months.

    Revenue$0
    Operating Income-$50.96M
    Pretax Income-$50.43M
    Net Income-$49.72M
    EBITDA-$49.35M
    EBIT-$50.43M
    Reported EPS (TTM)-$1.57

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 13.07% of the $59.43M in total assets.

    Cash and Equivalents$943.00K
    Total Debt$0
    Net Cash$943.00K
    Net Cash Per Share$0.01
    Working Capital$31.19M
    Shareholder Equity$7.77M
    Book Value Per Share$0.09
    Tangible Book Value-$12.06M
    Total Assets$59.43M
    Total Liabilities$6.66M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$22.55M
    FCF Per Share-$0.26

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Dividends and Yields

    RNTX does not pay a dividend.

    Buyback Yield-174.71%
    Shareholder Yield-174.71%

    Stock Splits

    The last split was a 1-for-20 reverse split on Nov 11, 2022.

    Last Split DateNov 11, 2022
    Split TypeReverse split
    Split Ratio1:20

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About RNTX

    What is RNTX's market cap?

    Rein Therapeutics has a market cap of $34.51M. Its enterprise value, which adds debt and subtracts cash, is $33.56M.

    How many shares of RNTX are outstanding?

    Rein Therapeutics has 88.33M shares outstanding. The count is up 235.06% from a year earlier.

    Does RNTX pay a dividend?

    No. Rein Therapeutics does not pay a dividend.

    How much debt does RNTX have?

    Rein Therapeutics has $0 of total debt and $943.00K of cash and equivalents, a net cash position of $943.00K.